Global X Management Co LLC decreased its stake in Heron Therapeutics Inc (NASDAQ:HRTX) by 11.2% in the 2nd quarter, Holdings Channel reports. The firm owned 27,805 shares of the biotechnology company’s stock after selling 3,501 shares during the quarter. Global X Management Co LLC’s holdings in Heron Therapeutics were worth $1,080,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Aperio Group LLC lifted its stake in Heron Therapeutics by 14.4% in the 2nd quarter. Aperio Group LLC now owns 11,261 shares of the biotechnology company’s stock valued at $437,000 after purchasing an additional 1,416 shares during the last quarter. BNP Paribas Arbitrage SA lifted its stake in Heron Therapeutics by 18.6% in the 1st quarter. BNP Paribas Arbitrage SA now owns 11,229 shares of the biotechnology company’s stock valued at $310,000 after purchasing an additional 1,761 shares during the last quarter. Swiss National Bank lifted its stake in Heron Therapeutics by 1.8% in the 1st quarter. Swiss National Bank now owns 100,300 shares of the biotechnology company’s stock valued at $2,768,000 after purchasing an additional 1,800 shares during the last quarter. Jane Street Group LLC lifted its stake in Heron Therapeutics by 10.7% in the 1st quarter. Jane Street Group LLC now owns 20,811 shares of the biotechnology company’s stock valued at $574,000 after purchasing an additional 2,005 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its stake in Heron Therapeutics by 12.6% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 19,010 shares of the biotechnology company’s stock valued at $525,000 after purchasing an additional 2,131 shares during the last quarter.

In other news, CFO Robert Hoffman sold 30,000 shares of the stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $38.17, for a total transaction of $1,145,100.00. Following the completion of the sale, the chief financial officer now directly owns 1,280 shares in the company, valued at $48,857.60. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, President Robert Rosen sold 129,469 shares of the stock in a transaction on Friday, June 29th. The stock was sold at an average price of $39.59, for a total transaction of $5,125,677.71. Following the sale, the president now owns 132,109 shares of the company’s stock, valued at $5,230,195.31. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 3,085,469 shares of company stock valued at $111,612,708. Corporate insiders own 16.20% of the company’s stock.

Shares of NASDAQ HRTX opened at $32.70 on Wednesday. Heron Therapeutics Inc has a 52-week low of $14.40 and a 52-week high of $42.90.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.14. Heron Therapeutics had a negative net margin of 411.41% and a negative return on equity of 112.35%. The firm had revenue of $17.28 million during the quarter, compared to analysts’ expectations of $12.82 million. During the same period in the prior year, the company posted ($0.80) EPS. The company’s revenue was up 103.1% on a year-over-year basis. sell-side analysts forecast that Heron Therapeutics Inc will post -2.2 EPS for the current fiscal year.

Several brokerages recently commented on HRTX. Oppenheimer increased their price objective on shares of Heron Therapeutics from $34.00 to $50.00 and gave the company an “outperform” rating in a research note on Friday, June 22nd. Cantor Fitzgerald reissued a “buy” rating and issued a $40.00 price objective on shares of Heron Therapeutics in a research note on Thursday, June 21st. Leerink Swann increased their price objective on shares of Heron Therapeutics to $46.00 and gave the company an “outperform” rating in a research note on Friday, June 22nd. Mizuho reissued a “buy” rating and issued a $41.00 price objective on shares of Heron Therapeutics in a research note on Friday, June 22nd. Finally, Cowen restated a “buy” rating and issued a $54.00 price target on shares of Heron Therapeutics in a research report on Thursday, June 21st. One analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $50.50.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Story: Marijuana Stocks

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.